Additional studies will be required to delineate these signaling networks, their impact on tumorigenesis and response to therapies, including resistance to PI3K-family inhibitors in TNBC patients, and to determine whether these networks are active in other breast-cancer subtypes and/or other forms of cancer. Here, PIK3CA is linked to cancer.